Healthcare
Based on ARK ETF real-time + 13F quarterly filings
13F data may be delayed up to 90 days.
※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.
CRISPR Therapeutics AG is a gene editing company developing transformative gene-based medicines for serious diseases using its revolutionary CRISPR/Cas9 platform. Their main products include CASGEVY, a gene-edited cell therapy for hemoglobinopathies, and various CAR T cell therapies and in vivo gene editing programs for oncology, cardiovascular disease, and type 1 diabetes. The company is a leader in the field, with strategic partnerships and a portfolio targeting significant unmet medical needs.
AI-generated summary. Not investment advice.